GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
March 02, 2023 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
January 09, 2023 07:30 ET
|
GH Research PLC
Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device for GH001 progressed, IND...
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022 07:05 ET
|
GH Research PLC
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 23, 2022 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
May 18, 2022 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
March 28, 2022 07:04 ET
|
GH Research PLC
DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and...
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
December 06, 2021 07:10 ET
|
GH Research PLC
DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
December 06, 2021 07:00 ET
|
GH Research PLC
Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change...
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
September 23, 2021 17:25 ET
|
GH Research PLC
DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...